BUSINESS● LOWOct 1 · Oct 1, 2026, 6:04 PM
Spyre draws new Overweight at J.P. Morgan on IBD potential
Seeking Alpha Tech · global
J.P. Morgan has issued a new "Overweight" rating for Spyre, citing its potential in Inflammatory Bowel Disease (IBD). This analyst rating provides an investment perspective for the company.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS9m agoFifth Third Bancorp Non-GAAP EPS of $1.13 beats by $0.05, revenue of $3.28B misses by $60MSeeking Alpha TechBUSINESS10m agoMedallion Financial to buy back $15M in preferred securities for $11MSeeking Alpha Tech